KALA PHARMACEUTICALS INC

KALA NASDAQ

KhanhC.Hoang

Most recent notes from BoA, "KALA provided updates on the preclinical programs, such as tyrosine kinase inhibitor program in retinal diseases (e.g. wet AMD), selective glucocorticoid receptor modulators (SEGRMs) and novel steroids. Mgmt. believes there is high unmet need in areas, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME)...

shlobby

Looks like history will repeat here. Perfect cup and handle on the daily first go around.. Next 2 months should remain flat then into a move up pending any news.

scottieguru292

It seems as though its selling off till earnings......i might get back in , if earnings lookout is +

Mauriello

Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease -- FDA Sets PDUFA Goal Date of October 30, 202 The idea is to go long hoping to get the good news from the FDA.

bpm.sanders

watch

yares

BUY STOP LIMIT EN 8.01

yares

ACCIONES AMERICANAS GRAN POTENCIAL MUESTRO VIDEO DETALLADO DE OPERACION EN INTERACTIVE BROKERS.

19:17

mnovo

request daily double

mickeymfa

NASDAQ:KALA KALA PHARMACEUTICALS INC $KALA is forming a CUP & Handle formation with a leading BO on the OBV index. The stock had also a lot of insider buying power and positive news with their EYSUVIS (a dry eye disease)

Samuel12_1980

MA200 above at 5.2 Defiantly Long above MA200 And not for any suggestion. Good-luck

Samuel12_1980

Clinical trial for EYSUVIS (KPI-121) - top line results of Phase III expected on first Q of 2020. The concern is : cash position as of September 30 was $97.6 million, compared to $170.9 million as of December 31, 2018. I do not suggest to buy\sell . Good-luck

Samuel12_1980

I see a good chance for long, only if market will take that stock to above 4.85$. Good-luck Fox

InvestorsWatchlist

4-week base. Looking for a break above 4.15

TopMarketGainers

As earnings approach NASDAQ:KALA is taking a very bullish trajectory and seemingly some positioning is taking place. Currently the 200 &100 day MA's are converging and will hopefully avoid a bearish cross , if the price can break above we believe it to a good entry point. AVERAGE ANALYSTS PRICE TARGET $19.57 AVERAGE ANALYSTS RECOMMENDATION buy P/E...

Cream4349

$KALA $LABU $LABD This is my first published idea on Tradingview. I play biotech and pdufa run up and data releases. KALA has a pdufa aug 15th, based on the chart it looks to be heading into a bullish run into possible FDA approval. I made three resistance points to watch out based on the 50 and 200 moving averages as well as prior resistance points. GLTA!!!...

Samuel12_1980

Only then, we can think out of the Box.

Samuel12_1980

MA50 supporting below as well

Samuel12_1980

Current support - MA30